| Autoantibodies against type I IFNs in patients with life-threatening COVID-19 P Bastard, LB Rosen, Q Zhang, E Michailidis, HH Hoffmann, Y Zhang, ... Science 370 (6515), eabd4585, 2020 | 2670 | 2020 |
| Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Q Zhang, P Bastard, Z Liu, J Le Pen, M Moncada-Velez, J Chen, M Ogishi, ... Science 370 (6515), eabd4570, 2020 | 2293 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1762 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1402 | 2021 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 804 | 2021 |
| Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission S Karthikeyan, JI Levy, P De Hoff, G Humphrey, A Birmingham, K Jepsen, ... Nature 609 (7925), 101-108, 2022 | 346 | 2022 |
| Emergence and rapid transmission of SARS-CoV-2 B. 1.1. 7 in the United States NL Washington, K Gangavarapu, M Zeller, A Bolze, ET Cirulli, ... Cell 184 (10), 2587-2594. e7, 2021 | 287 | 2021 |
| Long-term COVID-19 symptoms in a large unselected population ET Cirulli, KM Schiabor Barrett, S Riffle, A Bolze, I Neveux, S Dabe, ... medrxiv, 2020.10. 07.20208702, 2020 | 183 | 2020 |
| Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2 B. 1.1. 7 in the United States NL Washington, K Gangavarapu, M Zeller, A Bolze, ET Cirulli, ... MedRxiv, 2021 | 107 | 2021 |
| SARS-CoV-2 variant Delta rapidly displaced variant Alpha in the United States and led to higher viral loads A Bolze, S Luo, S White, ET Cirulli, D Wyman, A Dei Rossi, H Machado, ... Cell Reports Medicine 3 (3), 2022 | 91 | 2022 |
| HLA-A∗ 03: 01 is associated with increased risk of fever, chills, and stronger side effects from Pfizer-BioNTech COVID-19 vaccination A Bolze, I Neveux, KMS Barrett, S White, M Isaksson, S Dabe, W Lee, ... Human Genetics and Genomics Advances 3 (2), 2022 | 48 | 2022 |
| Rapid displacement of SARS-CoV-2 variant B. 1.1. 7 by B. 1.617. 2 and P. 1 in the United States A Bolze, ET Cirulli, S Luo, S White, D Wyman, A Dei Rossi, T Cassens, ... MedRxiv, 2021 | 46 | 2021 |
| S gene dropout patterns in SARS-CoV-2 tests suggest spread of the H69del/V70del mutation in the US NL Washington, S White, KMS Barrett, ET Cirulli, A Bolze, JT Lu MedRxiv, 2020.12. 24.20248814, 2020 | 43 | 2020 |
| A second update on mapping the human genetic architecture of COVID-19 M Kanai, SJ Andrews, M Cordioli, C Stevens, BM Neale, M Daly, A Ganna, ... Nature 621 (7977), E7-E26, 2023 | 42 | 2023 |
| Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative G Butler-Laporte, G Povysil, JA Kosmicki, ET Cirulli, T Drivas, S Furini, ... PLoS genetics 18 (11), e1010367, 2022 | 40 | 2022 |
| Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial PK Judge, N Staplin, KJ Mayne, C Wanner, JB Green, SJ Hauske, ... The Lancet Diabetes & Endocrinology 12 (1), 51-60, 2024 | 33 | 2024 |
| Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial N Staplin, R Haynes, PK Judge, C Wanner, JB Green, J Emberson, ... The Lancet Diabetes & Endocrinology 12 (1), 39-50, 2024 | 32 | 2024 |
| Saccharomyces cerevisiae mitochondria are required for optimal attractiveness to Drosophila melanogaster KM Schiabor, AS Quan, MB Eisen PloS one 9 (12), e113899, 2014 | 27 | 2014 |
| Cardiomyopathy prevalence exceeds 30% in individuals with TTN variants and early atrial fibrillation KMS Barrett, ET Cirulli, A Bolze, C Rowan, G Elhanan, JJ Grzymski, ... Genetics in Medicine 25 (4), 100012, 2023 | 20 | 2023 |
| Positive predictive value highlights four novel candidates for actionable genetic screening from analysis of 220,000 clinicogenomic records KMS Barrett, A Bolze, Y Ni, S White, M Isaksson, L Sharma, E Levin, ... Genetics in Medicine 23 (12), 2300-2308, 2021 | 19 | 2021 |
